Tags

Type your tag names separated by a space and hit enter

Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways.
Biochem J. 2001 Nov 01; 359(Pt 3):525-35.BJ

Abstract

The pleitropic actions of tumour necrosis factor-alpha (TNF) are transmitted by the type I 55 kDa TNF receptor (TNFR1) and type II 75 kDa TNF receptor (TNFR2), but the signalling mechanisms elicited by these two receptors are not fully understood. In the present study, we report for the first time subtype-specific differential kinase activation in cell models that respond to TNF by undergoing apoptotic cell death. KYM-1 human rhabdomyosarcoma cells and HeLa human cervical epithelial cells, engineered to overexpress TNFR2, displayed c-Jun N-terminal kinase (JNK) activation by wild-type TNF, a TNFR1-specific TNF mutant and a TNFR2-specific mutant TNF in combination with an agonistic TNFR2-specific monoclonal antiserum. A combination of the TNFR2-specific mutant and agonistic antiserum elicited maximal endogenous or exogenous TNFR2 responsiveness. Moreover, alternative expression of a TNFR2 deletion mutant lacking its cytoplasmic domain rendered the cells unable to activate JNK activity through this receptor subtype. The profile of JNK activation by TNFR1 was more transient than that of TNFR2, with TNFR2-induced JNK activity also being more sensitive to the caspase inhibitor, benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone. Conversely, only activation of the TNFR1 could stimulate mitogen-activated protein kinase (MAPK) or p38 MAPK activities in a time-dependent manner. The role of TNFR2 activation in enhanced apoptotic cell death was confirmed with agonistic monoclonal antisera in cells expressing high levels of TNFR2. Activation of TNFR2 alone elicited cell death, but full TNF-induced death required stimulation of both receptor types. These findings indicate that efficient activation of TNFR2 by soluble TNFs is achievable with co-stimulation by antisera, and that both receptors differentially modulate extracellular signal-regulated kinases contributing to the cytokine's cytotoxic response.

Authors+Show Affiliations

Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11672426

Citation

Jupp, O J., et al. "Type II Tumour Necrosis Factor-alpha Receptor (TNFR2) Activates c-Jun N-terminal Kinase (JNK) but Not Mitogen-activated Protein Kinase (MAPK) or P38 MAPK Pathways." The Biochemical Journal, vol. 359, no. Pt 3, 2001, pp. 525-35.
Jupp OJ, McFarlane SM, Anderson HM, et al. Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochem J. 2001;359(Pt 3):525-35.
Jupp, O. J., McFarlane, S. M., Anderson, H. M., Littlejohn, A. F., Mohamed, A. A., MacKay, R. H., Vandenabeele, P., & MacEwan, D. J. (2001). Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. The Biochemical Journal, 359(Pt 3), 525-35.
Jupp OJ, et al. Type II Tumour Necrosis Factor-alpha Receptor (TNFR2) Activates c-Jun N-terminal Kinase (JNK) but Not Mitogen-activated Protein Kinase (MAPK) or P38 MAPK Pathways. Biochem J. 2001 Nov 1;359(Pt 3):525-35. PubMed PMID: 11672426.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. AU - Jupp,O J, AU - McFarlane,S M, AU - Anderson,H M, AU - Littlejohn,A F, AU - Mohamed,A A, AU - MacKay,R H, AU - Vandenabeele,P, AU - MacEwan,D J, PY - 2001/10/24/pubmed PY - 2002/1/5/medline PY - 2001/10/24/entrez SP - 525 EP - 35 JF - The Biochemical journal JO - Biochem J VL - 359 IS - Pt 3 N2 - The pleitropic actions of tumour necrosis factor-alpha (TNF) are transmitted by the type I 55 kDa TNF receptor (TNFR1) and type II 75 kDa TNF receptor (TNFR2), but the signalling mechanisms elicited by these two receptors are not fully understood. In the present study, we report for the first time subtype-specific differential kinase activation in cell models that respond to TNF by undergoing apoptotic cell death. KYM-1 human rhabdomyosarcoma cells and HeLa human cervical epithelial cells, engineered to overexpress TNFR2, displayed c-Jun N-terminal kinase (JNK) activation by wild-type TNF, a TNFR1-specific TNF mutant and a TNFR2-specific mutant TNF in combination with an agonistic TNFR2-specific monoclonal antiserum. A combination of the TNFR2-specific mutant and agonistic antiserum elicited maximal endogenous or exogenous TNFR2 responsiveness. Moreover, alternative expression of a TNFR2 deletion mutant lacking its cytoplasmic domain rendered the cells unable to activate JNK activity through this receptor subtype. The profile of JNK activation by TNFR1 was more transient than that of TNFR2, with TNFR2-induced JNK activity also being more sensitive to the caspase inhibitor, benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone. Conversely, only activation of the TNFR1 could stimulate mitogen-activated protein kinase (MAPK) or p38 MAPK activities in a time-dependent manner. The role of TNFR2 activation in enhanced apoptotic cell death was confirmed with agonistic monoclonal antisera in cells expressing high levels of TNFR2. Activation of TNFR2 alone elicited cell death, but full TNF-induced death required stimulation of both receptor types. These findings indicate that efficient activation of TNFR2 by soluble TNFs is achievable with co-stimulation by antisera, and that both receptors differentially modulate extracellular signal-regulated kinases contributing to the cytokine's cytotoxic response. SN - 0264-6021 UR - https://www.unboundmedicine.com/medline/citation/11672426/Type_II_tumour_necrosis_factor_alpha_receptor__TNFR2__activates_c_Jun_N_terminal_kinase__JNK__but_not_mitogen_activated_protein_kinase__MAPK__or_p38_MAPK_pathways_ L2 - https://portlandpress.com/biochemj/article-lookup/doi/10.1042/0264-6021:3590525 DB - PRIME DP - Unbound Medicine ER -